LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study

Publication | Closed Access

DOI

Citations

References

2021

Year

Thomas Powles, V. Chistyakov, V. Beliakouski, Andrey Semenov, Els Everaert, Y. Baranau, Víctor Moreno, Begoña P. Valderrama, Yann Vano, G. Del Conte,

Annals of Oncology

Lba27 ErdafitinibUrologyNorse StudyGenitourinary CancerMedicinePathologyAdvanced Urothelial CarcinomaFibroblast Growth FactorCancer TreatmentOncology